anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This project will offer two training approaches targeting difficulties with goal-directed functioning associated with traumatic brain injury. Both approaches will be delivered remotely via tele-rehabilitation and augmented by digital apps - an intervention framework that addresses known barriers to engagement (e.g., convenience and access) and provides tools to intensify training. The study will be open to eligible Veterans (ages 21-60 years old) with history of mild-to-moderate TBI who experience difficulties with cognitive-emotional regulation and goal-directed functioning. After screening for eligibility and providing informed consent, participants will be allocated by permuted block randomization into one of two treatments: Education to optimize brain functioning (OPT), which will teach Veterans about brain health, brain injury and factors that affect brain functioning, or training in goal-directed state regulation skills (GSR), which will teach Veterans skills for regulating cognitive-emotional functioning during goal pursuit. A special emphasis on outreach will be to recruit student Veterans with TBI.

Each intervention will be matched for delivery method, expectation of benefit, workload and attention, and overall duration. Training will last approximately five weeks, accommodating typical academic schedules. Participants will undergo multi-level assessments at baseline (prior to interventions), immediately after training, and at 3 months follow-up, administered in-person by staff at study sites. In order to investigate effects on goal-directed functioning at multiple levels, assessments will include (1) measures of performance on neurocognitive tasks; (2) functional performance on complex, goal-based tasks; (3) ratings of changes in functioning in personal life, and (4) progress toward personal goals as measured with goal attainment scaling procedures. Data will be analyzed to assess immediate and long term changes associated with each intervention; immediate and long-term differences between the interventions; and moderators and mediators of intervention effects.
A method is provided for applying a sugarless coating to chewing gum pieces, confections, as well as medicinals in the form of pills or tablets, which method comprises the steps of applying to center portions of said comestible, coating syrup comprising an aqueous solution of normally sweet hygroscopic material (e.g. sorbitol, mannitol, maltitol, isomaltitol or hydrogenated starch hydrolysate), a binder (e.g. gum arabic), an anti-sticking compound (e.g. calcium carbonate), and a dispersing agent, (e.g. titanium dioxide) and applying to said so- treated center portions a coating dusting mix comprising said normally sweet hygroscopic material in dry form, at least a portion of said dry hygroscopic material being absorbed on the coating syrup applied to said center portions to form a coating on said center portions. Optionally the steps of applying said coating syrup and then applying coating dusting mix are repeated, as necessary, to build up a coating of desired thickness on the center portions.
The invention relates to a nymphaea-tetragona whitening spot-removing face-pasted mask. The main compositions of liquid essence comprises nymphaea-tetragona root extractive, evening primrose oil, citrus bigarradia flower essential oil, cypress essential oil, natural citric acid and natural chitosan, and the face-pasted mask is prepared by immersing a non-woven fabric mask into the compounded liquid essence. The face-pasted mask is mainly applied to intensive nursing of skin, such as whitening, spot removing, dullness prevention and skin color brightening. The face-pasted mask belongs to the technical field of therapeutic cosmetic. The face-pasted mask employs nymphaea-tetragona root extractive as the main whitening spot-removing composition, the compositions are completely extracted from pure natural biont, and the face-pasted mask is not added with any chemical compositions. Natural chitosan is utilized as a face-pasted mask matrix, evening primrose oil is employed as base oil of the liquid essence, the corrosion compositions are natural antiseptics coming from marine organisms, and then natural citric acid is utilized as an acid-alkali adjusting agent. The pH value of the face-pasted mask is adjusted to be suitable for weak acidity of skin, and the prepared face-pasted mask has the characteristics that the face-pasted mask is capable of efficiently whitening, removing spots, preventing wrinkles, resisting ageing, realizing anti-allergy restoration and brightening skin color, and is free of toxicity, free of stimulation, green and environment-friendly.
BACKGROUND AND OBJECTIVES: Surgical treatment of soft tissue sarcoma (STS) involves wide resection of the tumor, which can necessitate soft tissue reconstruction with local or free tissue flaps. This retrospective study compares cost, surgical and oncologic outcomes between patients undergoing reconstruction with immediate versus delayed flap coverage following STS resection.
METHODS: Thirty-four patients who underwent planned flap reconstruction following resection of primary STS were identified retrospectively. Twenty-four (71%) received immediate reconstruction during the index surgery and 10 (29%) underwent planned delayed reconstruction. Preoperative patient-specific metrics, tumor characteristics, and surgical and patient outcomes were collected. Total hospital charges associated with every encounter during the perioperative period were obtained.
RESULTS: Patient demographics, comorbidities, tumor metrics, and surgical characteristics were equivalent between groups. Postoperative wound complications, reoperations, readmissions, and disease-specific survival did not differ between cohorts. Costs associated with each reconstruction strategy were equivalent on bivariate and multivariate testing, when accounting for operating room time, hospital length of stay, and reoperation rate.
CONCLUSIONS: Our study identifies no significant difference in patient outcome measures or cost between planned immediate and delayed flap reconstruction following STS resection. These results support the implementation of either treatment strategy in keeping with patient-centered, multidisciplinary care principles.
Patients receive a single dose of vismodegib PO on an empty stomach. Beginning 7 days later, patients receive vismodegib PO on an empty stomach daily on days 1-28.
1416351 Intercommunication systems A VERRIEST 27 April 1973 [2 April 1973] 20129/73 Heading H4K A telephone system, e.g. for use in a hospital or like institution, includes a monitoring station 1 and a plurality of telephones 20 interconnected therewith either directly or via sub-stations 2 in the form of concentrators, and the system is characterized in that each telephone includes means for looping the line with the hand set on-hook and a signal generator for transmitting a tone over a looped line to the monitoring station so as to identify the calling subscriber, e.g. a hospital patient. In the embodiment a hospital patient or other person likely to require attention either lifts his handset to operate hook switch 22 or causes a switch 23 to be closed to short the hook switch, e.g. by pressing a key or in a further embodiment by hitting the subset to activate a transducer which causes the switch to close. A signal generator then transmits a tone, e.g. a single frequency or a combination of frequencies from the subset to the monitoring station where a visual and/or audible signal is given to indicate the calling line. An operator can then speak to the calling subscriber. The operator may extend the connection to aid posts 12 where duty doctors, nurses or welfare workers &c. may be available or to emergency services 13 such as a hospital, ambulance, police, fire-brigade. Where the subscribers are liable to require medical attention a card index 15 may be provided at the monitoring station which is arranged such that a card relating to a calling subscriber is automatically selected on receipt of the calling frequency tone of the subscriber. It may also be arranged for instruments such as a thermometer, an analytical probe or a device measuring pulse rate to be read via the telephone lines, the depression of a further key at the subset causing signals representing the readings of such instruments to be transmitted to the monitoring stations. Where sub-stations 2, i.e. concentrators are used the monitoring station may be connected with the sub-station 2 via separate signalling and speech paths 3, 4.
PURPOSE: To obtain a compound for medicinal purpose to compensate the insufficiency of several minerals in esp, the bone tissue, through such processes as removing ballast ingredients or the like from eggshells by mechanical treatment, washing, rinsing, dehydration, drying, grinding, sieving and sterilization. CONSTITUTION: First, ballast ingredients, contaminants and films adhered to the inner surface of eggshells are removed by mechanical treatment (pref. centrifugal separation) from eggshells freed from albumen and yolk as the contents, followed by thoroughly washing the eggshells, which, in turn, rinsed, and then freed from water pref. by the use of a centrifugal separator, and dried in hot air. Subsequently, the resultant eggshells are ground into powder <=150 (pref. 10-80)μm in particle size, which is further pulverized, and then sieved, and the resultant powder is sterilized at a temperature enough to deactivate pathogenic and conditionally pathogenic microorganisms, thus obtaining the objective compound for medicinal purpose containing each specific amount of Ca, Mg, P, carbonate and N through biological binding as well as microelements and other biological elements.
Cancer immunotherapies effective for treating tumors are disclosed. A cytosolic receptor that detects viral ribonucleic acid (RNA), retinoic-acid-inducible protein 1 (RIG-I), is activated by a synthetic double-stranded oligonucleotide pUUC Auk. In one implementation, RIG-I is activated by a single-stranded oligonucleotide agonist formulated with a squalene emulsion (SE) adjuvant. Activation of RIG-I with pUUC Auk results in slower tumor growth. Formulation with a SE adjuvant increases the ability of RIG-I agonists to slow tumor growth. The novel agonist and formulations provided herein are effective for slowing the growth of new tumors and reducing further growth of established tumors. RIG-I agonist/adjuvant formulations may be administered to a subject by any of multiple routes including intratumoral injection.
Breast cancer is becoming a more common disease in Africa, with a high proportion of cases developing among women under age 50. Despite this, there is scant information on predisposing factors in African populations. We are proposing a multidisciplinary case-control study at three hospitals in Accra and Kumasi that treat the majority of breast cancers in Ghana. We have begun this investigation as a pilot endeavor and are seeking approval for continuation into a full-scale effort, which over the two years following the pilot will result in a total of approximately 2,000 interviewed cases and 2,000 population controls. Tumor tissue samples are being sought from cases in order to classify them into subtypes (including triple negative tumors, which predominate among young African women). A detailed questionnaire is being administered in hospital and anthropometry measurements are being taken. Additionally, subjects are being asked to donate blood, saliva, and stool samples for assessment of genetic and other biologic markers. Similar materials are being collected from population controls. In addition to providing unique data relevant for improving prevention activities, this study will build capacity for additional research activities in Ghana.
Prostate cancer (PCa) is the most common cancer among men in the United States and the second leading cause of cancer-related deaths. Metastatic castration-resistant PCa is still a fatal disease. On the other hand, between 2016 and 2020, about 70% of PCa cases were diagnosed at a localized stage. Evolving data demonstrates that men with low-grade cancers treated with definitive therapies may now be exposed to morbidities of overtreatment and poor quality of life, with little or no benefit in terms of cancer specific mortality. Active surveillance (AS) is thus the recommended management strategy for men with low-grade disease. Although this subgroup of men have reported anxiety during the AS period, they account to be highly motivated to make positive lifestyle changes to further reduce their risk of PCa progression, underscoring the urgent need to identify novel strategies for preventing progression of localized PCa to metastatic disease through pharmacologic means, an approach termed chemoprevention. Although several promising agents and approaches have been examined over the past 2 decades, currently, there are several limitations in the approach used to systematically examine agents for chemoprevention targeting men on AS. The goal of this review is to summarize the current agents and approaches evaluated, targeting men on AS, recognize the gaps, and identify a contemporary and comprehensive path forward. Results of these studies may inform the development of phase III clinical trials and ultimately provide a strategy for clinical chemoprevention in men on AS, for whom, currently, there are no options for reducing the risk of progression to metastatic disease.
A novel dipeptide compound which inhibits the enzymatic activity of an HIV  protease and is represented by formula (I); and an anti-AIDS agent containing the dipeptide compound as the active ingredient. [In the formula, R?1~, R?2~, and R?3~ each represents C~1-4? alkyl, alkoxy, hydrogen, etc. (provided that not all of R?1~, R?2~, and R?3~ are hydrogen) and R?2~ and R?3~ may be bonded to each other to form a ring; R?4~ represents C~1-4? alkyl or hydrogen; X  represents methylene or sulfur; Y represents, e.g., a five- or six-membered monocycle or aryloxyalkyl having up to 12 carbon atoms (provided that the aromatic ring may have been substituted by alkyl, etc.); and Z represents a C~1-6? aliphatic hydrocarbon or an aromatic hydrocarbon having up to 12 carbon atoms (provided that this aromatic ring may have been substituted by alkyl, etc. or at least one carbon atom of the aromatic hydrocarbon may have been replaced with a heteroatom).]
Among those who applied to the clinic, those who want to follow their diet will be randomized into this group. Patients in this group will be followed by a personalized diet and will receive 30 g/day lyophilized Cornus mas L. fruit powder for their one portion of fruit a day.
This is a Phase I randomized, double-blind, placebo-controlled trial in 50 males and non-pregnant females, 18 to 49 years old, inclusive, who are in good health and meet all eligibility criteria. This clinical trial is designed to assess the safety, reactogenicity, and immunogenicity of inactivated A/H5N1 influenza vaccine administered intradermally (ID) with topical Aldara or control cream as a 2-dose regimen. The vaccine will be administered using the MicronJet600(TM) device. Subjects will be assigned randomly to 1 of 2 treatment arms (25 subjects per treatment arm) to receive 2 doses of A/H5N1 IIV administered ID with topical Aldara or control cream. Group A will receive two doses of A/H5N1 IIV (9 mcg HA/dose) ID with pre-application of topical Aldara on Days 1 and 22. Group B will receive two doses of A/H5N1 IIV (9 mcg HA/dose) ID with pre-application of topical control cream on Days 1 and 22. The duration of this study will be approximately 20 months with patient participation duration approximately 7 months. The primary objectives of this study are: 1) to assess the safety and reactogenicity after 2 doses of A/H5N1 IIV vaccine containing 9 mcg HA per dose administered ID approximately 21 days apart with topical Aldara or control cream; 2) to assess the serum HAI antibody responses 21 days after receipt of the 2nd dose of A/H5N1 IIV administered ID at 9 mcg HA per dose with topical Aldara or control cream. The secondary objectives are: 1) to assess unsolicited non-serious adverse events (AEs) following receipt of 2 doses of A/H5N1 IIV administered ID approximately 21 days apart with topical Aldara or control cream; 2) to assess medically-attended adverse events (MAAEs) including new-onset chronic medical conditions (NOCMCs), and potentially immune mediated medical conditions (PIMMCs) following receipt of two doses of A/H5N1 IIV administered ID approximately 21 days apart with topical Aldara or control cream for six months after last vaccination; 3) to assess the serum neutralizing (Neut) antibody responses 21 days following receipt of the 1st and 2nd dose of A/H5N1 IIV administered ID with topical Aldara or control cream; 4) to assess the serum HAI antibody responses 21 days following receipt of the 1st dose of A/H5N1 IIV administered ID with topical Aldara or control cream; 5) to assess the serum HAI and Neut antibody responses 7 days following receipt of the 2nd dose of A/H5N1 IIV administered ID with topical Aldara or control cream.
PURPOSE:To obtain an impression material for the sole use to the tissue of operation field and the bone surface, by adding an X-ray contrasting medium opaque to X-ray and having low toxicity and stimulation to a base having low toxicity to the living body and stimulation to the tissue. CONSTITUTION:The objective impression material composition for the sole use to the operation field tissue or the bone surface is composed of (A) an impression material having no or extremely low toxicity to the living body and stimulation to the tissue (e.g. silicone resin or vinylsilicone resin, etc.), (B) an X- ray contrasting medium opaque to X-ray and having no toxicity to the living body and stimulation to the tissue (e.g. Fe2O3, BaSO4, etc.) and if necessary, (C) a colorant (e.g. carbon black). The addition of the X-ray contrasting medium to the impression material enables the easy and sure inspection of the impression material existing in the operation field tissue or bone surface by X-ray photography. Accordingly, the residual impression material can be removed completely from the operation field by the secondary operation. The impression material is discernible with naked eye without using the X-ray photography when a colorant is compounded to the material.
In the pilot study subjects will be treated with SATIVEX® (THC/cannabidiol combination in a buccal spray) using the same approach as outlined below for the randomized controlled trial. In the twelve-week, double-blind, placebo-controlled study visits will occur weekly during the medication phase of the study. The medication will be self-titrated over three weeks and a target quit date will be set up at Day 21. There will be a total of 12 weeks of drug exposure. Throughout these 12-weeks, all participants will receive a combination of pharmacotherapy (Sativex Spray or Placebo Spray) associated with a weekly intervention of combined Motivational Enhancement Therapy and Cognitive Behavioral Therapy (MET/CBT) in accordance with the intervention practices shown to be effective in treatment of cannabis dependence. The intervention will be adapted from the Brief Counselling for Marijuana Dependence manual published by the Substance Abuse and Mental Health Services Administration (SAMHSA). At each study visit, vital signs and self-report ratings will be collected. In addition, the subjects will have to come daily to the centre to assess medication usage and will be asked to provide urine sample (two times weekly) and blood sample weekly. As there may be compliance issues, a contingency management approach will be also implemented.
SYNERGY™ everolimus eluting stent (EES). Patients will have OCT follow-up 1 month after the index procedure.
Participants received 3 doses of placebo matching with MEDI6012 by IV push. A loading dose on Day 1 and maintenance doses on Days 3 and 10.
The patient group will include 60 patients with type II DM. They will be subdivided into three groups according to albumin-creatinine ratio ,normoalbuminuric group(less than 30mg/g),which will include 20 patients, microalbuminuric group (ACR =30-300 mg/), which will include 20 patients, and macroalbuminuric group (ACR more than 300mg/g),which will include 20 patients.
CNS stimulants, including QUILLIVANT XR, used to treat ADHD are associated with peripheral vasculopathy, including Raynaud’s phenomenon. Signs and symptoms are usually intermittent and mild; however, sequelae have included digital ulceration and/or soft tissue breakdown. Effects of peripheral vasculopathy, including Raynaud’s phenomenon, were observed in post-marketing reports and at the therapeutic dosage of CNS stimulants in all age groups throughout the course of treatment. Signs and symptoms generally improved after dosage reduction or discontinuation of the CNS stimulant. 

Careful observation of digital changes is necessary during QUILLIVANT XR treatment. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for QUILLIVANT XR-treated patients who develop signs or symptoms of peripheral vasculopathy.
PURPOSE:To obtain a solid powdery cosmetic having good practical properties such as spreadability, adhesivity and durability on skin, refreshing feeling and excellent impact resistance by using a specific amount of a triester compound, an oily component containing silicone oil, etc., and a powdery component as essential components. CONSTITUTION:The objective cosmetic contains (A) 1-6wt.% (based on the total cosmetic) of a triester compound of a 8-18C straight-chain saturated fatty acid and glycerol, (B) 3-15wt.% of an oily component containing 1-4wt.% based on the total cosmetic) of a silicone oil (e.g. dimethylpolysiloxane) having a viscosity of 10-200cSt and (C) 85-97wt.% of a powdery component (e.g. titanium oxide, talc, mica and kaolin). The sum of the ester compound and the silicone oil is >=30wt.% based on the total oil component. The solid powdery cosmetic can be used e.g. as face powder, foundation and eye shadow.
An intervention study with a cross-over research design will be conducted among a sample of 60 employees who do remote or hybrid work. The intervention phase lasts in total of four weeks. During the first week (control phase), the participants continue their daily routine as normal. During the second week of the intervention, a half of the participants are randomised to visit a nearby natural area after finishing work (exposure to nearby nature). The other half of the participants are randomised to view virtual nature videos with VR goggles after finishing work (exposure to virtual nature). On the third week of the intervention, the participants complete nature exposure the other way around. That is, those participants who took part first in exposure to nearby nature will view virtual nature, and vice versa. On the fourth week of the intervention, the participants take part in a semi-structured focus group interview.

Recovering from work in nearby nature and virtual nature is examined through multidisciplinary perspectives of health, well-being, and tourism. The aim of the research is to find new ways of promoting work stress recovery, psychological detachment and restoration among employees when they are making the transition between work time and personal time. These research findings are particularly relevant for fields in which there has been a growing trend for remote or hybrid work. This research is funded by the Finnish Work Environment Fund (Project Number: 220076).